These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1127 related articles for article (PubMed ID: 29895557)

  • 1. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
    Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
    Kuchay MS; Krishan S; Mishra SK; Choudhary NS; Singh MK; Wasir JS; Kaur P; Gill HK; Bano T; Farooqui KJ; Mithal A
    Diabetologia; 2020 Nov; 63(11):2434-2445. PubMed ID: 32865597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.
    Sattar N; Fitchett D; Hantel S; George JT; Zinman B
    Diabetologia; 2018 Oct; 61(10):2155-2163. PubMed ID: 30066148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial.
    Kahl S; Gancheva S; Straßburger K; Herder C; Machann J; Katsuyama H; Kabisch S; Henkel E; Kopf S; Lagerpusch M; Kantartzis K; Kupriyanova Y; Markgraf D; van Gemert T; Knebel B; Wolkersdorfer MF; Kuss O; Hwang JH; Bornstein SR; Kasperk C; Stefan N; Pfeiffer A; Birkenfeld AL; Roden M
    Diabetes Care; 2020 Feb; 43(2):298-305. PubMed ID: 31540903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
    Cheung KS; Ng HY; Hui RWH; Lam LK; Mak LY; Ho YC; Tan JT; Chan EW; Seto WK; Yuen MF; Leung WK
    Hepatology; 2024 Oct; 80(4):916-927. PubMed ID: 38536017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
    Lin YH; Zhang ZJ; Zhong JQ; Wang ZY; Peng YT; Lin YM; Zhang HP; Tian JQ
    PLoS One; 2024; 19(5):e0302155. PubMed ID: 38701096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
    Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
    Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    Dig Dis Sci; 2020 Feb; 65(2):623-631. PubMed ID: 30684076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
    Gaborit B; Ancel P; Abdullah AE; Maurice F; Abdesselam I; Calen A; Soghomonian A; Houssays M; Varlet I; Eisinger M; Lasbleiz A; Peiretti F; Bornet CE; Lefur Y; Pini L; Rapacchi S; Bernard M; Resseguier N; Darmon P; Kober F; Dutour A
    Cardiovasc Diabetol; 2021 Mar; 20(1):57. PubMed ID: 33648515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Idilman IS; Keskin O; Elhan AH; Idilman R; Karcaaltincaba M
    Scand J Gastroenterol; 2014 May; 49(5):617-24. PubMed ID: 24694249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME
    Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
    Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
    Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
    Yoneda M; Honda Y; Ogawa Y; Kessoku T; Kobayashi T; Imajo K; Ozaki A; Nogami A; Taguri M; Yamanaka T; Kirikoshi H; Iwasaki T; Kurihashi T; Saito S; Nakajima A
    BMJ Open Diabetes Res Care; 2021 Feb; 9(1):. PubMed ID: 33593749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
    Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shi M; Zhang H; Wang W; Zhang X; Liu J; Wang Q; Wang Y; Zhang C; Guo X; Qiao Q; Cui C; Xu J; Wang J
    J Diabetes Complications; 2023 Oct; 37(10):108610. PubMed ID: 37722211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.